Celiac test kits match multi-centre study demands

The results of the recent Multi-Centre Celiac Serology Study undertaken to define the optimal serological screening approach to Celiac Disease clearly showed that dual or combined isotype (IgA+IgG) transglutaminase screening can be advocated as a sensitive and specific alternative to endomysial antibody testing in the assessment of Celiac Disease.

The manufacturer Aesku Diagnotics reports that its AESKULISA tTg ELISA kits ‘performed excellently’, and the AESKULISA Celicheck was ‘even placed first as the best dual isotype transglutaminase kit of all assays tested.’ The Elisa kits have a unique composition, the firm explains. ‘Human recombinant tissue transglutaminase is cross-linked with gliadin-specific peptides resulting in the creation of neo-epitopes of tTg. The tests are highly specific as no cross-reactions with gliadin occur.’
* The FDA has approved the improved Aeskulisa tTg IgA and tTg IgG tests for the detection of tissue transglutaminase (tTg) antibodies.
 

20.11.2008

More on the subject:

Related articles

Photo

News • Integration of digital pathology and AI tools

Digital pathology partnership to streamline workflows and enhance diagnostics

Digital pathology software company Fujifilm Healthcare Europe and Ibex Medical Analytics, specializing in AI-powered cancer diagnostics, announce a formal partnership to support efficient and…

Photo

News • NHS rollout

Liquid biopsy: new ‘blood test-first’ approach for lung cancer

A new ‘liquid biopsy’ test can help fast-track lung cancer patients to receive targeted therapy up to two weeks earlier, while helping avoid further tests and treatments including chemotherapy.

Photo

Article • San Antonio Breast Cancer Symposium (SABCS)

Young women and breast cancer: research in focus

At the San Antonio Breast Cancer Symposium (SABCS), three experts presented new approaches and study results for the treatment of breast cancer in young women.

Related products

Subscribe to Newsletter